• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Capstar Special Purpose Acquisition Corp.

    1/14/22 9:04:44 AM ET
    $CPSR
    Business Services
    Finance
    Get the next $CPSR alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39362
    Issuer: GELESIS HOLDINGS, INC.
    Exchange: NEW YORK STOCK EXCHANGE LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 405 West 14th Street
    Austin TEXAS 78701
    Telephone number: (512) 619-2922
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Units, each consisting of one share of Class A Common Stock and one-half of one Warrant
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2022-01-14 By Christopher Rances Senior Analyst
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CPSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPSR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPSR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Capstar Special Purpose Acquisition Corp.

      25-NSE - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      1/14/22 9:04:44 AM ET
      $CPSR
      Business Services
      Finance
    • Capstar Special Purpose Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

      1/12/22 4:09:39 PM ET
      $CPSR
      Business Services
      Finance
    • SEC Form 425 filed by Capstar Special Purpose Acquisition Corp.

      425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      1/10/22 6:26:59 AM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cavanaugh Kathryn converted options into 12,825 shares, disposed of 12,825 shares and acquired 12,825 shares

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      1/18/22 5:00:38 PM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Capstar Special Purpose Acquisition Corp.

      SC 13G - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      9/20/21 4:14:46 PM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

      Gelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and the change in body weight after six months of therapy GS200 demonstrated a highly favorable Categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications; the overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the placebo group ~6 out of 10 GS200-treated adults achieved at least 5% weight loss ("Responders"), losing

      5/4/22 6:35:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study

      New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis), released today a poster prPesentation at the World of Microbiome annual meeting in Vienna. The preclinical study showed administration of one of Gelesis' proprietary superabsorbent hydrogels, Gel-B, significantly shifted the composition of the m

      4/29/22 6:05:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care